Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus - 24/04/13

Doi : 10.1016/j.jaad.2008.01.012

Dedee F. Murrell, MD ^a, Sarah Dick, MD ^b, A.R. Ahmed, JD ^c, Masayuki Amagai, MD ^d, Maria A. Barnadas, MD ^e, Luca Borradori, MD ^f, Jean-Claude Bystryn, MD ^g, Giuseppe Cianchini, MD ^h, Luis Diaz, MD ⁱ, David Fivenson, MD ^j, Russell Hall, MD ^k, Karen E. Harman, MD ^l, Takashi Hashimoto, MD ^m, Michael Hertl, MD ⁿ, Nico Hunzelmann, MD ^o, Pilar Iranzo, MD ^p, Pascal Joly, MD ^q, Marcel F. Jonkman, MD ^r, Yasuo Kitajima, MD, PhD ^s, Neil J. Korman, MD, PhD ^t, Linda K. Martin, MD ^a, Daniel Mimouni, MD ^u, Amit G. Pandya, MD ^v, Aimee S. Payne, MD, PhD ^b, David Rubenstein, MD, PhD ⁱ, Hiroshi Shimizu, MD ^w, Animesh A. Sinha, MD, PhD ^x, David Sirois, MD ^y, Detlef Zillikens, MD ^z, Victoria P. Werth, MD ^b,^aa,^⁎
^a Department of Dermatology at St George Hospital, University of NSW, Sydney, Australia
^b Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
^d Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
^e Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
^f Department of Dermatology, Hôpital Cantonal Universitaire, Geneva, Switzerland
^g Department of Dermatology, New York University Medical Center, New York, New York
ⁱ Department of Dermatology, University of North Carolina, Chapel Hill, North Carolina
^k Division of Dermatology, Duke Medical Center, Durham, North Carolina
^l Division of Dermatology, University Hospitals Leicester, Leicester, United Kingdom
^m Division of Dermatology, Kurume University School of Medicine, Kurume, Japan
ⁿ Division of Dermatology, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Germany
^o Division of Dermatology, Universitätshautklinik Köln, Köln, Germany
^p Division of Dermatology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
^r Division of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
^s Division of Dermatology, Gifu University School of Medicine, Gifu, Japan
^t Division of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio
^u Division of Dermatology, Rabin Medical Center, Petah-Tikva, Israel
^v Division of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
^w Division of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
^z Division of Dermatology, University of Luebeck, Luebeck, Germany
^aa Philadelphia Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania
^c Department of Medicine, Center for Blistering Diseases, New England Baptist Hospital, Boston, Massachusetts
^h Immunodermatology Department, Istituto Dermopatico dell’Immacolata, I.R.C.C.S., Via dei Monti di Creta, Rome, Italy
^j Private Practice, Ann Arbor, Michigan
^q Clinique Dermatologique, Hopital Charles Nicolle, Rouen, France
^x Center for Investigative Dermatology, Division of Dermatology and Cutaneous Sciences, Michigan State University, East Lansing, Michigan
^y Department of Oral Medicine, New York University College of Dentistry, New York, New York

Reprint requests: Victoria P. Werth, MD, Department of Dermatology, University of Pennsylvania, 2, Rhodes Pavilion, 3600 Spruce St, Philadelphia, PA 19119.

Abstract

Our scientific knowledge of pemphigus has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in pemphigus. A major obstacle in comparing therapeutic outcomes between centers is the lack of generally accepted definitions and measurements for the clinical evaluation of patients with pemphigus. Common terms and end points of pemphigus are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. This consensus statement from the International Pemphigus Committee represents 2 years of collaborative efforts to attain mutually acceptable common definitions for pemphigus. These should assist in development of consistent reporting of outcomes in future studies.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : AAD, NIH, PDAI, PSS, PV

Plan

	Funding for meeting support of the International Pemphigus Committee was provided by the International Pemphigus and Pemphigoid Foundation. Additional partial support was provided by a grant from the National Institutes of Health K24-AR 02207 (Dr Werth).
	Conflicts of interest: None declared.

Export

Vol 58 - N° 6

P. 1043-1046 - juin 2008 Retour au numéro

Article précédent

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
Alexa B. Kimball, Dafna Gladman, Joel M. Gelfand, Kenneth Gordon, Elizabeth J. Horn, Neil J. Korman, Gretchen Korver, Gerald G. Krueger, Bruce E. Strober, Mark G. Lebwohl, National Psoriasis Foundation

| Article suivant

The human papillomavirus vaccine
Warren R. Heymann

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus - 24/04/13

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL